Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

Journal of Surgical Oncology

Volumn 72, Issue 3, 1999, Pages 162-169

  Ghamande, Sharad A ^a   Piver, M Steven ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Ovarian cancer; Paclitaxel; Primary peritoneal cancer; Recurrence; Topotecan

Indexed keywords

CISPLATIN; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032708102     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199911)72:3<162::AID-JSO9>3.0.CO;2-0     Document Type: Article

References (24)

1. Landis SH, Murray T, Bolder S, et al.: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-31.
2. Mcguire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
3. Stuart G, Bertelsen K, Magioni C, et al.: Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment for advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish Intergroup Trial [Abstract]. Proc Am Soc Clin Oncol 1998;17:361A.
4. Blackledge G, Lawton F, Redman C, et al.: Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design for phase II trials. BMJ 1989;59:650-653.
5. Ozols RF: Treatment of recurrent ovarian cancer: Increasing options - "recurrent results." J Clin Oncol 1997;15:2177-2180.
6. Armstrong D, Rowinsky E, Donehower R, et al.: A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:275A.
7. Creemers GJ, Bolis G, Gore M, et al.: Topotecan, an active drug in the second line treatment of epithelial ovarian cancer: Results of large European phase II study. J Clin Oncol 1996;14:3056-3061.
8. Gordon A, Bookman M, Malmstrom H, et al.: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial [Abstract]. Proc Am Soc Clin Oncol 1996;15:282A.
9. Kudelka AP, Tresukosol D, Edwards CL, et al.: Phase II study of intravenous topotecan as a 5 day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
10. Gordon A, Carmichael J, Malfetano J, et al.: Final analysis of a phase III randomized study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian cancer (OC): International Topotecan Study Group [Abstract]. Proc Am Soc Clin Oncol 1998;17:356A.
11. ten Bokkel Huinink W, Gore M, Carmichael J, et al.: Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
12. Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1998;16:405-410.
13. Abu-Rustum NR, Aghajanian C, Barakat RR, et al.: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997;24(Suppl. 15):62-67.
14. van der Burg MEL, de Wit R, Stoter G, et al.: Phase I study of weekly cisplatin (P) and weekly or 4 weekly Taxol (T): a highly active regimen in advanced epithelial ovarian cancer (OC) [Abstract], Proc Am Soc Clin Oncol 1998;17:355A.
15. Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-993.
16. Kaufmann M, Bauknecht T, Jonat W, et al.: Gemcitabine (Gem) in cisplatin-resistant ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1995;14:272A.
17. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-291.
18. Johnson RK, McCabe FL, Yu Y: Combination regimens with topotecan in animal tumor models. Ann Oncol 1992;3:85-88.
19. Romanelli S, Perego P, Pratesi G, et al.: In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 1998;41:385-390.
20. Rowinsky EK, Kaufmann SH, Baker SD, et al.: Sequences of topotecan and cisplatin: A phase I, pharmacologic, and in vitro study to examine sequence dependence. J Clin Oncol 1996;14: 3074-3084.
21. Miller AA, Hargis JB, Lilenbaum RC, et al.: Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B study. J Clin Oncol 1994;12: 2743-2750.
22. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug stabilized topoisomerase I-DNA cleavable complexes as mechanism of cell killing by camptothecin. Cancer Res 1989;49: 5077-5082.
23. Miller AA, Lilenbaum RC, Lynch TJ, et al.: Treatment related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel . J Clin Oncol 1996;14:1964-1965.
24. Lilenbaum RC, Miller AA, Batist G, et al.: Phase I study of continuous IV infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462) [Abstract]. Proc Am Soc Clin Oncol 1996;15:485A.